Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for rare dermatological diseases including RDEB and JEB caused by nonsense mutations. Eloxx receives $3 million upfront and is eligible for up to $470 million in milestones plus tiered royalties on global sales.